Advanced Proteome Therapeutics Reports Positive Results and Advances Collaboration with Heidelberg Pharma

Advanced Proteome Therapeutics (TSXV:APC) (FSE: 0E8), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma.

As quoted in the press release:

Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC’s proprietary site-selective protein modification technology and Heidelberg Pharma’s proprietary ATAC technology, featuring the mushroom toxin amanitin, has led to conjugates that possess high target-specific anti-cancer potency established in several human cancer cell types.

The Company is pleased to announce that the lead ADC has now impressively demonstrated complete tumor regression at a single low dose in two challenging mouse models of human cancer (JIMT-1, NCI-N87) over extended observation periods with clear superiority over benchmark molecules used as positive controls. The potency and efficacy exhibited by the ADC is profound and the studies are still ongoing, as the improved condition of the test animals permitted a longer-term evaluation than originally contemplated.

Click here to read the full press release.